Ignite Creation Date:
2024-05-06 @ 3:08 PM
Last Modification Date:
2024-10-26 @ 1:43 PM
Study NCT ID:
NCT04535102
Status:
WITHDRAWN
Last Update Posted:
2022-05-09
First Post:
2020-07-23
Brief Title:
POLABR for Relapsed or Refractory DLBCL
Sponsor:
University of Colorado Denver
Organization:
University of Colorado Denver
Study Overview
Official Title:
POLATUZUMAB PLUS BENDAMUSTINE PLUS RITUXIMAB POLABR AS SALVAGE THERAPY PRIOR TO AUTOLOGOUS STEM CELL TRANSPLANT FOR PATIENTS WITH RELAPSED OR PRIMARY REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Status:
WITHDRAWN
Status Verified Date:
2022-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Lack of sufficient patient population
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a phase II multicenter open-label study of polatuzumab vedotin administered by IV infusion in combination with standard doses of bendamustine B and rituximab R in transplant-eligible patients with relapsed or refractory DLBCL A total of 22 patients will be enrolled over a period of 2 years through the University of Colorado and additional study sites if applicable Study treatment will be given in 21-day cycles for patients with DLBCL
Detailed Description:
The first day of treatment will constitute Cycle 1 Day 1 Patients will be treated with a minimum of three cycles and up to a maximum of 6 cycles to optimize responses prior to ASCT based on investigator discretion
All patients will be evaluated for safety and efficacy according to the schedules of assessments
All patients will be assessed for response to treatment by the investigator with the use of standard criteria according to the Modified Lugano Response Criteria at the following time points
At the time of screening
At the time of primary response assessment 3 weeks after completion of study treatment ie 3 weeks after Cycle 3 Day 1 or after last dose of study medication
Imaging at these timepoints must include FDG-PET 18F-fluorodeoxyglucose-positron emission tomography and a diagnostic-quality CT scan with both oral and IV contrast A combined PETCT scan is encouraged if feasible CT scans with oral and IV contrast should include neck chest abdomen and pelvic scans In patients for whom contrast is contraindicated eg patients with contrast allergy or impaired renal clearance or patient denial PET-CT scans without contrast are permitted so long as they permit consistent and precise measurement of target lesions during the study treatment period
Patients will also be evaluated every 3 months for 2 years or until disease progression death withdrawal of consent or initiation of another anti-cancer therapy Tumor assessments should also be performed to confirm clinical suspicion of relapse or disease progression for documentation The study will end when all patients enrolled have been followed until death have withdrawn consent have been lost to follow-up until 2-year follow up or the Sponsor-investigator decides to end the trial whichever occurs first
All patients will be evaluated for safety and efficacy according to the schedules of assessments
All patients will be assessed for response to treatment by the investigator with the use of standard criteria according to the Modified Lugano Response Criteria at the following time points
At the time of screening
At the time of primary response assessment 3 weeks after completion of study treatment ie 3 weeks after Cycle 3 Day 1 or after last dose of study medication
Imaging at these timepoints must include FDG-PET 18F-fluorodeoxyglucose-positron emission tomography and a diagnostic-quality CT scan with both oral and IV contrast A combined PETCT scan is encouraged if feasible CT scans with oral and IV contrast should include neck chest abdomen and pelvic scans In patients for whom contrast is contraindicated eg patients with contrast allergy or impaired renal clearance or patient denial PET-CT scans without contrast are permitted so long as they permit consistent and precise measurement of target lesions during the study treatment period
Patients will also be evaluated every 3 months for 2 years or until disease progression death withdrawal of consent or initiation of another anti-cancer therapy Tumor assessments should also be performed to confirm clinical suspicion of relapse or disease progression for documentation The study will end when all patients enrolled have been followed until death have withdrawn consent have been lost to follow-up until 2-year follow up or the Sponsor-investigator decides to end the trial whichever occurs first
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| P30CA046934 | NIH | None | httpsreporternihgovquickSearchP30CA046934 |